Monitoring blood flow responses during topical ALA-PDT by Becker, Theresa L. et al.
Monitoring blood flow responses during topical 
ALA-PDT 
Theresa L. Becker,
1 Anne D. Paquette,
1 Kenneth R. Keymel,
2 Barbara W. Henderson,
2 
and Ulas Sunar
2* 
1Department of Dermatology, Roswell Park Cancer Institute, Buffalo, NY, 14263 
2Department of Cell Stress Biology & PDT Center, Roswell Park Cancer Institute, Buffalo, NY, 14263 
*ulas.sunar@roswellpark.org 
Abstract: Photodynamic therapy (PDT) using topical 5-aminolevulinic acid 
(ALA) is currently used as a clinical treatment for nonmelanoma skin 
cancers. In order to optimize PDT treatment, vascular disruption early in 
treatment must be identified and prevented. We present blood flow 
responses to topical ALA-PDT in a preclinical model and basal cell 
carcinoma patients assessed by diffuse correlation spectroscopy (DCS). Our 
results show that ALA-PDT induced early blood flow changes and these 
changes were irradiance dependent. It is clear that there exists considerable 
variation in the blood flow responses in patients from lesion to lesion. 
Monitoring blood flow parameter may be useful for assessing ALA-PDT 
response and planning. 
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1. Introduction 
Photodynamic therapy (PDT) is an evolving cancer treatment modality that involves 
administration of a photosensitizer which reacts with oxygen when exposed to light, forming 
reactive oxygen species and causing subsequent tissue damage [1]. The photosensitizer can be 
applied systemically or topically. The most commonly used systemic clinical photosensitizer 
is porfimer sodium (Photofrin) [2]. A downside of this agent is the skin photosensitivity that 
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induces accumulation of the endogenous photosensitizer protoporphyrin IX (PpIX), is an 
approach in treatment of many cancer types [3]. The application of topical ALA followed by 
light is advantageous in that it does not cause body-wide skin photosensitization [3]; it also is 
highly selective, causing negligible damage to connective tissue and minimal scarring. 
Topical ALA-PDT has become an attractive treatment option for non-melanoma skin 
carcinomas, especially when treating large areas at a single session or multiple lesions on the 
same patient [2–6]. 
The efficacy of PDT is highly dependent on the tissue oxygen level, which in turn can be 
affected by blood flow [7,8]. Many photosensitizers lead to destruction of vasculature which 
is one of the mechanisms by which PDT is effective at destroying tumors. Blood flow may 
change during PDT and these changes can be useful early biomarkers for therapy outcome 
and planning. Measurement of the cutaneous microcirculation is of clinical importance for 
monitoring and determining the efficacy of PDT treatment. In order to optimize ALA-PDT, it 
is necessary to identify and prevent the vascular shutdown that can occur early in treatment. A 
temporary shutdown in vasculature will decrease the delivery of oxygen which will severely 
limit the effectiveness of  the remaining PDT treatment. Early identification of vascular 
disruption will allow adjustment of treatment parameters in real time to improve the 
effectiveness of therapy. It will be important to find the optimal time at which these vascular 
effects provide improved efficacy [9]. Diffuse correlation spectroscopy (DCS), relying on the 
intrinsic dynamic contrast of moving blood cells, does not require contrast agent 
administration, and is highly suitable for monitoring blood flow during PDT. To date DCS has 
been successfully employed in monitoring of therapies, such as PDT [8,10–12], chemo-
radiation [13], and neoadjuvant chemotherapy [14]. Using DCS, Yu et al. [8] showed early 
blood flow changes correlated well with the Photofrin-mediated PDT efficacy in a murine 
tumor model. 
The reports on blood flow responses due to ALA-PDT are few, mainly focused on post 
treatment times and the results showed great variability [15–21]. The variability is likely due 
to differences in tumor characteristics (type, depth, size), PpIX concentration, treatment 
protocols and dosimetry [15,20–23]. Here we present blood flow responses monitored from 
the beginning to the end of ALA-PDT using DCS. We investigated the effects of different 
irradiances since irradiance is known to be an important determinant for PDT responses, 
including vascular responses. Our results from Colon-26 bearing mice show that topical ALA 
induced early blood flow decreases at all irradiances (10 mW/cm
2, 35 mW/cm
2, 75 mW/cm
2), 
followed by a rapid increase and eventually a gradual decrease. Lower irradiance resulted in a 
smaller initial blood flow drop, followed by a blood flow increase. We also collected clinical 
data of ALA-PDT of superficial and nodular basal cell carcinomas (BCC). In contrast to 
results from mice, we observed a distinct pattern of early increase in blood flow in superficial 
lesions. The elevated blood flow was persistent throughout the treatment. In nodular lesions, 
blood flow stayed relatively constant throughout the treatment. 
2. Methods 
2.1 Measurement protocol 
Animal experiments were approved by the Institutional Animal Care and Use Committee at 
Roswell Park Cancer Institute (RPCI). Female BALB/c mice 7-14 weeks of age were 
inoculated subcutaneously (s.c.) with Colon-26 (1 x 10
6 cells in 50 µL) on the right posterior 
shoulder. The mice underwent treatment when tumors reached 6.5-8.5 mm in diameter. In 
order to keep the mice immobile, they were injected intraperitoneally with ketamine-xylazine 
(KX) 10 minutes before measurements were started and placed on a 36 °C heating pad. A 
thermocouple was inserted under the mouse skin to monitor temperature throughout 
treatment, which remained fairly constant throughout treatment. Mice were shaved and 
depilated with Nair® the day before injection of tumor cells. The treatment light source was 
an argon pumped dye laser set for 635 nm output. Treatment light irradiances were set to 75 
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2, 35 mW/cm
2, or 10 mW/cm
2 and the treatment field diameter was ~16 mm, covering 
each tumor and surrounding normal tissue. The total light doses for 35 mW/cm
2  and 75 
mW/cm
2 were 80 J/cm
2. For the 10 mW/cm
2 of irradiance, the total light dose was 37.5 J/cm
2. 
This was decided due to the increased difficulty in keeping the mice anesthetized for longer 
than 75 minutes. ALA (Sigma, Missouri), 20% in topical vehicle solution (Dusa, 
Massachusetts), was applied to the tumors ~3 hours before treatment. Control mice had PDT 
light only without applied ALA. Five mice were measured for each irradiance and for both 
treated and control groups; therefore, the total of 30 mice were measured in this study. 
The patient treatment and measurement protocol was approved by the RPCI Institutional 
Review Board. Patients with basal cell carcinomas were accrued for the measurement of 
blood flow during ALA-PDT. There was a ~4 hour incubation time between the application of 
the ALA and the start of light treatment. ALA (20%) in topical vehicle solution was applied to 
the lesions. The light source for the PDT treatment was a Coherent dye laser pumped by an 
Argon ion laser (Spectra Physics), and the light was delivered by a single quartz lens fiber. 
The treatment beam was centered on the lesion with the beam diameter slightly larger than 
lesion diameter. Nodular BCCs (nBCCs, N = 2) were treated with 150 mW/cm
2, and 
superficial BCCs (sBCCs, N = 4) were treated initially with 40 mW/cm
2 and followed by 150 
mW/cm
2  after reaching the 90% photobleaching point (measured concurrently with 
fluorescence spectroscopy [24–26]. Patients treated using the initial irradiances of 150 
mW/cm
2 (nBCCs) received local injections of lidocaine prior to the start of treatment in order 
to prevent pain [27]. For all treatments, the room temperature was maintained around 26 °C. 
2.2 Diffuse optical blood flow 
Diffuse Correlation Spectroscopy (DCS) was utilized to monitor blood flow as described 
previously [5,9–17]. The DCS instrument was described in our recent published report [11]. 
Briefly, the instrument had a long coherence length laser (785nm, CrystaLaser), four single 
photon-counting detectors (SPCD, Perkin-Elmer), and an autocorrelator board 
(Correlator.com) (Fig. 1a). The autocorrelator board calculated intensity autocorrelation 
functions and photon arrival times that were recorded by a computer [5,9]. From the 
normalized intensity autocorrelation function, g2(r,τ), the diffuse electric field temporal 
autocorrelation function (g1(r,τ)), was extracted by using Siegert relation [28], g2(r,τ) = 1 + 
β|g1(r,τ)|
2. Here, r is the source detector separation, τ is the autocorrelation time delay, and β is 
a constant related to detected number of speckles. It was shown that the electric field 
autocorrelation function satisfies the correlation diffusion equation and analytical solutions 
can be obtained under special conditions [21,22]. It can be shown that the temporal decay rate 
of the electric field autocorrelation function is a function of optical parameters and αDB, if one 
assumes the effective blood flow speed is characterized by effective diffusion coefficient (DB) 
for the blood cells [13,14,29,30]. Here, α is the probability that a scattering event in tissue is 
from a moving scatterer, and is related to blood volume fraction. Therefore, αDB characterizes 
blood flow [11,12,22]. The system was assumed to be ergodic. More generalized schemes for 
non-ergodic systems closely representing living tissue have been reported recently [23–25]. 
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Fig. 1. a) Schematic diagram of the instrument and noncontact and contact probes. The DCS 
setup consists of 785 nm laser, single photon counting detector (SPCD), correlator (Corr), and 
laptop (PC). Laser light is split in two; one for contact probe, and another for noncontact probe. 
In the probe tip, the larger red dot at the center represents source fiber, and other three black 
dots represent detector fibers. The separations between source and detector fibers were 3mm. 
The open circle is the source position. Lens setup for noncontact probe is also shown with f1 = 
60mm, f2 = 40mm. Filter was 785/10 nm band-pass. b) Picture of the noncontact probe. 
During experiments in mice, laser light was split (90:10) into two with 10% of light 
directed into a contact probe where source and one detector fiber were set at a distance of 2 
mm at the hip of each animal to monitor the systemic blood flow changes, while 90% laser 
light was directed into a custom non-contact probe that allowed assessing blood flow response 
continuously at the tumor site during PDT light irradiation (Fig. 1a). In noncontact probe (Fig. 
1a, b), a relay lens allowed projecting the probe tip onto the tumor. Two NIR coated plano-
convex lenses (Edmund Optics) with 30 mm diameter and focal points of 60 mm (f1) and 40 
mm (f2) were used to construct the relay lens. A bandpass filter (785/10 nm, Chroma) was 
placed between the lenses to block the PDT light from reaching the detectors. Source fiber 
and three detector fibers were set at equal distance of 3 mm at the probe tip. Our relay lens 
setup demagnified the source detector spacing from 3 mm to 2 mm at the tumor surface. A 
source detector spacing of 2 mm allowed approximate penetration depth of 0.67 mm to 1 mm 
[11]. All data was normalized to the contact probe located away from the PDT irradiation site 
to eliminate systemic reaction effects such as changes in skin temperature. 
The noncontact probe was not practical for continuous measurements during PDT in the 
clinic since patients could move causing changes in the position and focus of the probe. This 
necessitated a less bulky probe that could be taped to the patient. We also collimated the 
source and detector fibers as Gisler et al. [31] showed that a setup is much less sensitive to 
misalignment or disturbances if the observation beam is collimated to a diameter of ~1 mm 
instead of being focused. Source and two detector fibers were collimated with source-detector 
separations of 2 mm and 3 mm and 700 nm long pass (700LP) filters were installed into 
detection channels to remove treatment light (Fig. 2a). The collimated probe was validated 
against a contact probe in an Intralipid phantom (absorption coefficient, µa = 0.021 cm
−1 and 
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Fig. 2. a) Schematic diagram of the noncontact probe in the clinical instrument. Source and 
detector fibers were collimated with source-detector separations of 2 mm and 3 mm. 700nm 
long-pass (700LP) filters were installed into detection channels to remove treatment light. b) 
Particle diffusion coefficient (DB ) of Intralipid obtained with a contact and a collimated probe. 
scattering coefficient, μ’s = 10 cm
−1). The source-detector separation for both the collimated 
probe and the contact probe was 2.8 mm. Intralipid has a suspension of particles ranging in 
diameter from 260 nm to 300 nm. For 300 nm diameter polystyrene beads, the particle 
diffusion coefficient (DB) was extracted to be ~1.5 × 10
−8 cm
2 s
−1 [32]. As can be seen from 
Fig. 2b, our extracted DB values are very close to each other (1.545 ± 0.66 10
−8 cm
2 s
−1, for 
contact vs 1.543 ± 0.62 10
−8 cm
2 s
−1 for collimated), matching well with the expected DB for a 
300 nm particle diameter. 
3. Results and discussion 
Figure 3 summarizes our preclinical results. It is clear from Fig. 3a that ALA-PDT induced 
acute early vascular changes: Initial quick drop was followed by an increase and a final 
gradual change towards initial levels for all irradiances. Lowest fluence rate results showed a 
very early increase. Error bars represents the standard error over five animals (N = 5). Lower 
irradiance resulted in a lower initial blood flow drop and a higher subsequent increase. 
Fluence-rate dependent differences in blood flow decreases were statistically significant 
(p<0.05, Wilcoxon rank sum test). The reasons for these blood flow patterns are not well 
understood. A possible explanation for early decrease may be due to constriction of the blood 
vessels arising from a lack of nitric oxide, since it has been shown that nitric oxide production 
  
 
Fig. 3. a) Relative blood flow changes in mice during ALA-PDT with different irradiances. b) 
Relative blood flow changes for light-only controls. 
#138316 - $15.00 USD Received 17 Nov 2010; revised 14 Dec 2010; accepted 15 Dec 2010; published 15 Dec 2010
(C) 2011 OSA 1 January 2011 / Vol. 2,  No. 1 / BIOMEDICAL OPTICS EXPRESS  128decreases in deoxygenated conditions [13] and deoxygenation can be caused by PDT 
consuming the oxygen. Then there may have been a temporary burst of blood flow causing an 
increase trend. Figure 3b shows that the control group (light only, no ALA) showed rather 
constant blood flow values throughout PDT treatment suggesting the changes in blood flow in 
treated mice were due to PDT effects as opposed to systemic effects due to anesthesia, 
temperature or light. 
Henderson et al. observed that ALA induced blood perfusion reduction using fluorescein 
methods in Colon-26 tumor (75 mW/cm
2, 135 J/cm
2) at 1 hr, 3 hr, 5 hr, and 24 hr post-PDT 
[18]. Van der Veen et al. [19] also observed a reduction at 4 hr and 10 hr post-PDT using the 
same methods in UVB-treated skin models (100 mW/cm
2, 100 J/cm
2). Leveckis et al. [16] 
studied blood flow during ALA PDT on the cremaster muscle in rats. They investigated 
irradiances of 105 mW/cm
2, 178 mW/cm
2, and 300 mW/cm
2 using a 390-460 nm light source. 
They found a rapid artery diameter decrease within 4 minutes to about 20% of the original 
value in the 178 mW/cm
2, and 300 mW/cm
2 cases followed a gradual increase. Schacht et al. 
[22] found a large decrease in red blood cell velocity and in functional vessel density at “high 
dose” (100 J/cm
2) but not in “low dose” (10 J/cm
2). This study was done in a skin fold 
chamber where the ALA was applied to the underside of the tumor and did not need to 
penetrate the epidermis so that levels may have been higher than typical. Herman et al. [15] 
did not see a blood flow decrease in Colon-26 tumor bearing mice treated at 55 to 68 mW/cm
2 
with 633 nm PDT light. They administered ALA by tail vein injection rather than topically as 
in our study; Schact et al. [22] showed that topically administered ALA resulted in much 
more microcirculatory effects than intravenously administered ALA. 
 
Fig. 4. Relative blood flow changes during clinical ALA-PDT of a) sBCC and b) nBCC 
lesions. Shaded area represents 40mW/cm2, otherwise 150mW/cm2. 
We also initiated blood flow measurements in our ongoing clinical trial of ALA-PDT for 
treatment of BCCs [25]. Although the current patient number is low and the treatment 
regimen is not the same for all of the lesions, we divided the data into two groups: nodular 
BCCs (nBCCs, lesions nBCC1 & nBCC2) treated with 150 mW/cm
2, and superficial BCCs 
(lesions sBCC1 to sBCC4) treated initially with 40 mW/cm
2 and followed by 150 mW/cm
2 
after reaching the 90% photobleaching point (measured concurrently with fluorescence 
spectroscopy [24–26]. Figure 4 summarizes our results from these lesions (sBCC1 divided by 
4 to be on the same scale). It is clear that there exists considerable variation in the blood flow 
responses from lesion to lesion. It is also clear that low irradiance caused a more pronounced 
increase in the early stage of the treatment in sBCCs (Fig. 4a), indicating more blood flow 
during treatment that should result in increased oxygenation and a therapeutic benefit. The 
elevated blood flow responses were persistent until completion of PDT treatment. In nodular 
lesions, blood flow did not show such a high increase trend but stayed relatively constant 
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preclinical findings. 
Blood flow changes due to clinical ALA-PDT have been discussed in several studies with 
differing results. Wang et al. [20] and Enejder et al. [21] reported blood flow increase after 
ALA-PDT in human BCCs by using laser Doppler imaging. These studies were done  at 
varying unstated irradiances under 100 mW/cm
2 and their estimated blood flow probing depth 
was in the range of 150-350 µm; meaning the signal originated primarily from the superficial 
layer. Interestingly they also observed elevated blood flow responses immediately after PDT 
for all of the sBCCs compared with the nBCCs. This difference in blood flow response may 
be due to epidermal layer, which usually covers nodular tumors and results in less of the 
dynamically scattered light from moving blood cells to be detected [21]. The range of 
thicknesses of the epidermis and dermis in human skin are 0.03-1.4 mm and 0.86-3 mm 
respectively [33,34], showing great variation from patient to patient, which may affect 
individual blood flow quantification significantly in clinical settings. This point also 
necessitates the use of a high resolution imaging modality such as ultrasound [35] so that 
probe could be adjusted if the thickness and depth were known as a priori information. Local 
injections of lidocaine during treatments of nBCCs might also have affected blood flow 
changes in nBCCs. In contradiction to these blood flow increases after PDT, Herman et al. 
[15] showed a blood flow decrease in patients, but their treatment irradiance was 200 mW/cm
2 
and patients had different types of tumors: colon or rectum adenocarcinomas. Differences in 
irradiance, accumulated PDT dose and tumor vascularity may affect observed blood flow 
patterns [36]. PpIX content in the vasculature was unknown for these patients, but there is a 
possibility of more heterogeneity of PpIX distribution in nBCCs compared to sBCCs. This 
may be because the nodular tumors generally have larger regions of differentiation. Thickness 
and depth of tumors might have an effect on the response. Superficial tumors are generally 
more oxygenated due to possibility of getting oxygen from the surrounding air. 
Topical ALA-PDT causes very significant pain during treatment at conventional light 
irradiances (~75-150 mW/cm
2). The pain appears to be due to direct photodynamic activity on 
the cutaneous nerve endings, and thus is a mark of normal tissue damage. Our group 
published earlier that the pain level is dependent on the irradiance [27]. Fluence rates above 
50 mW/cm
2 are increasingly painful and fluence rates below that cause no or lesser pain. We 
have found that the use of painless irradiance of 40 mW/cm
2  to photobleach the 
photosensitizer PpIX to 80-90% of its initial level with a subsequent irradiance of 150 
mW/cm
2 to be painless in most patients. Our current protocol is designed to spare our patients 
from pain and excessive exposure to analgesics. Patients with superficial basal cell 
carcinomas accrued with the current protocol, which was the main reason for the difference in 
irradiances (40 mW/cm
2 vs 150 mW/cm
2) at the beginning of the treatment. 
4. Conclusion 
We presented preliminary results of changes in blood flow during ALA-PDT in a preclinical 
model and recently initiated clinical studies for BCC patients. It can be concluded that in 
preclinical studies blood flow decreased during treatment in an irradiance dependent manner. 
The pattern of these blood flow changes is an initial early sharp decrease followed by an 
increase and then a more gradual decrease. ALA-PDT induced significant blood flow 
changes. We observed significant variation in each patient and lesion, thus emphasizing the 
importance of monitoring the treatment response on an individual basis. Extracted blood flow 
should be valuable for understanding and assessing the PDT dose adjustment and clinical 
response and feedback. The ongoing clinical trial and collection of data generating statistically 
significant data sets may show a clear trend in blood flow responses. 
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